

## Publikationen Klinische Pharmazie und Klinische Pharmakologie & Toxikologie 2007

1. Becker C, Brobert GP, Almqvist PM, Johansson S, Jick SS, Meier CR. Migraine and the Risk of Stroke, TIA, or Death in the UK (CME). *Headache* 2007;47(10):1374-84.
2. Belin GK, Krahenbuhl S, Hauser PC. Direct determination of valproic acid in biological fluids by capillary electrophoresis with contactless conductivity detection. *J Chromatogr B Analyt Technol Biomed Life Sci* 2007;847(2):205-9.
3. Bodmer M, Amico P, Mihatsch MJ, et al. Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient. *Nephrol Dial Transplant* 2007;22(8):2366-70.
4. Botomino A, Bruppacher R, Krahenbuhl S, Hersberger KE. Change of body weight and lifestyle of persons at risk for diabetes after screening and counselling in pharmacies. *Pharm World Sci* 2007.
5. Brauchli YB, Scholer A, Schwietert M, Krahenbuhl S. Undetectable phenytoin serum levels by an automated particle-enhanced turbidimetric inhibition immunoassay in a patient with monoclonal IgMlambda. *Clin Chim Acta* 2007.
6. Burri E, Ruegg S, Rutishauser J, Egger SS, Lampert ML. [Subtherapeutic blood levels of phenytoin due to a medication error]. *Schweiz Rundsch Med Prax* 2007;96(17):687-92.
7. Degen L, Drewe J, Piccoli F, et al. Effect of CCK-1 receptor blockade on ghrelin and PYY secretion in men. *Am J Physiol Regul Integr Comp Physiol* 2007;292(4):R1391-9.
8. Degen L, Matzinger D, Drewe J, et al. Role of free fatty acids in regulating gastric emptying and gallbladder contraction. *Digestion* 2006;74(3-4):131-9.
9. Egger SS, Ratz Bravo AE, Hess L, Schlienger RG, Krahenbuhl S. Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. *Drugs Aging* 2007;24(5):429-40.
10. Fluri F, Lyrer P, Gratwohl A, Raetz-Bravo AE, Steck AJ. Lead poisoning from the beauty case: neurologic manifestations in an elderly woman. *Neurology* 2007;69(9):929-30.
11. Giger U, Buchler M, Farhadi J, et al. Preoperative immunonutrition suppresses perioperative inflammatory response in patients with major abdominal surgery-a randomized controlled pilot study. *Ann Surg Oncol* 2007;14(10):2798-806.
12. Grauwiler SB, Scholer A, Drewe J. Development of a LC/MS/MS method for the analysis of cannabinoids in human EDTA-plasma and urine after small doses of *Cannabis sativa* extracts. *J Chromatogr B Analyt Technol Biomed Life Sci* 2007;850(1-2):515-22.

13. Haegeli L, Brunner-La Rocca HP, Wenk M, Pfisterer M, Drewe J, Krahenbuhl S. Sublingual administration of furosemide: new application of an old drug. *Br J Clin Pharmacol* 2007;64(6):804-9.
14. Harder J, Kummer O, Olschewski M, Otto F, Blum HE, Opitz O. Prognostic relevance of carbohydrate antigen 19-9 levels in patients with advanced biliary tract cancer. *Cancer Epidemiol Biomarkers Prev* 2007;16(10):2097-100.
15. Haschke M, Zhang YL, Kahle C, et al. HPLC-atmospheric pressure chemical ionization MS/MS for quantification of 15-F2t-isoprostane in human urine and plasma. *Clin Chem* 2007;53(3):489-97.
16. Indermitte J, Beutler M, Bruppacher R, Meier CR, Hersberger KE. Management of drug-interaction alerts in community pharmacies. *J Clin Pharm Ther* 2007;32(2):133-42.
17. Indermitte J, Burkolter S, Drewe J, Krahenbuhl S, Hersberger KE. Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients. *Drug Saf* 2007;30(1):71-80.
18. Indermitte J, Erba L, Beutler M, Bruppacher R, Haefeli WE, Hersberger KE. Management of potential drug interactions in community pharmacies: a questionnaire-based survey in Switzerland. *Eur J Clin Pharmacol* 2007;63(3):297-305.
19. Indermitte J, Reber D, Beutler M, Bruppacher R, Hersberger KE. Prevalence and patient awareness of selected potential drug interactions with self-medication. *J Clin Pharm Ther* 2007;32(2):149-59.
20. Jaccard Y, Walther S, Anderson S, et al. Influence of secondary infection on amputation in chronic critical limb ischemia. *Eur J Vasc Endovasc Surg* 2007;33(5):605-9.
21. Kesten F, Sutter R, Winter L, et al. [Really drunk?]. *Schweiz Rundsch Med Prax* 2007;96(45):1767-71.
22. Khanlari B, Bodmer M, Terracciano L, Heim MH, Fluckiger U, Weisser M. Hepatitis with Fibrin-Ring Granulomas. *Infection* 2007.
23. Knapp AC, Todesco L, Beier K, et al. Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores. *J Pharmacol Exp Ther* 2007.
24. Krahenbuhl S. Pharmakokinetische Prinzipien und Dosisanpassung. In: Schölmerich J, ed. *Medizinische Therapie*. 3 ed. Heidelberg: Springer Verlag; 2007:25-33.
25. Krahenbuhl S, Brauchli Y, Kummer O, et al. Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage. *Digestion* 2007;75(4):232-7.
26. Krahenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S. Drug-related problems in hospitals: a review of the recent literature. *Drug Saf* 2007;30(5):379-407.

27. Kummer O, Mossdorf E, Battegay M, et al. Treatment of an atazanivir associated grade 4 hyperbilirubinaemia with efavirenz. *Gut* 2007;56(10):1477-8.
28. Kunzel AR, Haschke M, Surber C, Lambrecht JT. [Mefenamic acid and other non-steroidal anti-inflammatory agents in dental practice. A review of the literature]. *Schweiz Monatsschr Zahnmed* 2007;117(1):12-8.
29. Lampert ML, Ratz Bravo AE, Brugger S, Haschke M. [Unexpected loss of therapeutic effect of oxcarbazepine]. *Schweiz Rundsch Med Prax* 2007;96(47):1843-8.
30. Laudi S, Weimann J, Haschke M, et al. Worsening of long-term myocardial function after successful pharmacological pretreatment with cyclosporine. *J Physiol Pharmacol* 2007;58(1):19-32.
31. Link B, Haschke M, Wenk M, Krahenbuhl S. Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2007;21(9):1531-40.
32. Lude S, Torok M, Dieterle S, et al. Hepatic effects of *Cimicifuga racemosa* extract in vivo and in vitro. *Cell Mol Life Sci* 2007.
33. Maier A, Zimmermann C, Beglinger C, Drewe J, Gutmann H. Effects of budesonide on P-glycoprotein expression in intestinal cell lines. *Br J Pharmacol* 2007;150(3):361-8.
34. Petitjean S, Ladewig D, Meier CR, Amrein R, Wiesbeck GA. Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. *Int Clin Psychopharmacol* 2007;22(5):292-8.
35. Philippson C, Hahn M, Schwabe L, Richter S, Drewe J, Schachinger H. Cardiovascular reactivity to mental stress is not affected by alpha2-adrenoreceptor activation or inhibition. *Psychopharmacology (Berl)* 2007;190(2):181-8.
36. Piccoli F, Degen L, MacLean C, et al. Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjects. *J Clin Endocrinol Metab* 2007;92(5):1814-20.
37. Ramazzina C, Zysset Aschmann Y, Kummer O, Ratz Bravo AE, Bodmer M. [Zoledronate-associated end stage renal failure and hypocalcaemia]. *Schweiz Rundsch Med Prax* 2007;96(17):673-6; quiz 7-8.
38. Schlatter P, Beglinger C, Drewe J, Gutmann H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. *Regul Pept* 2007;141(1-3):120-8.
39. Schlienger RG, Fedson DS, Jick SS, Jick H, Meier CR. Statins and the risk of pneumonia: a population-based, nested case-control study. *Pharmacotherapy* 2007;27(3):325-32.

40. Strom T, Haschke M, Boyd J, et al. Crossreactivity of Isolated Everolimus Metabolites With the Innofluor Certican Immunoassay for Therapeutic Drug Monitoring of Everolimus. *Ther Drug Monit* 2007;29(6):743-9.
41. Strom T, Haschke M, Zhang YL, et al. Identification of everolimus metabolite patterns in trough blood samples of kidney transplant patients. *Ther Drug Monit* 2007;29(5):592-9.
42. Sulz MC, Manz M, Grob P, Meier R, Drewe J, Beglinger C. Comparison of two antacid preparations on intragastric acidity--a two-centre open randomised cross-over placebo-controlled trial. *Digestion* 2007;75(2-3):69-73.
43. Vonbach P, Dubied A, Beer JH, Krahenbuhl S. Recognition and management of potential drug-drug interactions in patients on internal medicine wards. *Eur J Clin Pharmacol* 2007;63(11):1075-83.
44. Yam J, Kreuter M, Drewe J. Piper cubeba Targets Multiple Aspects of the Androgen-Signalling Pathway. A Potential Phytotherapy against Prostate Cancer Growth? *Planta Med* 2007.